



CHLOROQUINE PHOSPHATE 15 MG/ML ORAL SUSPENSION

(contains 9.3 mg/mL chloroquine base)

Date Prepared: ____ / ____ / 20 ____

LOT: NS _____

Expiry Date: ____ / ____ / 20 ____

Final Checked By: _____

INGREDIENTS	MFR	LOT #	EXPIRY DATE	FORMULA QUANTITY	QUANTITY USED	PREPARED	CHECKED
Chloroquine phosphate 250 mg tablet <i>(250 mg tablet contains 155 mg of chloroquine base)</i>	Novopharm/ aralen			3 tablets			
Ora-Blend				Qs to 50 mL			

Risk Summary:

Always follow policies & procedures for risk assessment/NAPRA level as determined by your own pharmacy department.

Equipment and PPE:

- Mortar and pestle
- Graduated cylinder
- Glass stirring rod
- Standard CHEO Level B PPE (hair bonnet, mask, +/- beard cover, clean gown and nitrile gloves)

Procedure:

Always follow departments training protocols and policies and procedures that are currently in place.

1. Place tablets in mortar and pour a small amount of vehicle over the tablets before levigating.
2. Using the pestle, levigate tablets to create a smooth paste.
3. Continue to levigate, adding vehicle in small amounts until the product is liquid enough to transfer to a graduated cylinder.
4. Rinse mortar several times with vehicle and add product to the graduated cylinder.
5. QS to final volume with vehicle.
6. Stir well and transfer to amber bottle. Label bottle appropriately.
7. Before washing, rinse equipment into medication disposal bin, and not directly into sink.

Quality Control:

- Final Appearance: White, opaque suspension
- Packaging: amber plastic bottles
- Storage & BUD: 60 days at room temperature, protect from light

Sample Label:



Children's Hospital of Eastern Ontario
Pharmacy Department

Children's Hospital of Eastern Ontario	
<u>CHLOROQUINE PHOSPHATE 15 MG/ML ORAL SUSPENSION</u>	
Shake Well. Room Temperature. Protect from Light	
Quantity:	
LOT:	Expiry:

Reference(s):

- Nahata MC, Hipple TF, Pediatric Drug Formulations, 4th ed. 2000 pp 27
- Trissel's Stability of Compounded Formulations, 2nd ed
- Allen, L & Erickson III, MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am J Health-Syst.Pharm. 1998; 55:1915-20.

Formulation Review:

Master Sheet Revision Dates: 8Jan07; May 2018; Apr 2019.